BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 15527055)

  • 1. An evaluation of clinical and histopathological status in paucibacillary leprosy patients after completion of fixed duration therapy.
    Mathew D; Kishore BN; Shwethadri GK; Sukumar ; Shetty NJ
    Indian J Lepr; 2004; 76(1):11-8. PubMed ID: 15527055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed duration MDT in paucibacillary leprosy.
    Mathai R; George S; Jacob M
    Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):237-41. PubMed ID: 2071980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed resolution versus treatment failure in paucibacillary leprosy patients under six months fixed duration multidrug therapy.
    Job CK; Jayakumar J; Aschhoff M
    Indian J Lepr; 1997; 69(2):131-42. PubMed ID: 9290964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse as histoid leprosy after receiving multidrug therapy (MDT); a report of three cases.
    Shaw IN; Ebenezer G; Rao GS; Natrajan MM; Balasundaram B
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):272-6. PubMed ID: 11221089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of single-dose ROM therapy plus low-dose convit vaccine as an adjuvant for treatment of paucibacillary leprosy patients with a single skin lesion.
    Majumder V; Saha B; Hajra SK; Biswas SK; Saha K
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):283-90. PubMed ID: 11221091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silent iritis in treated bacillary negative leprosy.
    Thompson K; Job CK
    Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):306-10. PubMed ID: 8862265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinico-pathological study of multidrug regimen in paucibacillary leprosy.
    Kar PK; Jha PK; Panayach JS; Snehi PS
    Indian J Lepr; 1988 Apr; 60(2):235-41. PubMed ID: 3192972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four-year follow-up results of a WHO-recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi.
    Boerrigter G; Pönnighaus JM; Fine PE; Wilson RJ
    Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):255-61. PubMed ID: 2071983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of leprosy patients with single lesions to MDT.
    Katoch K; Natrajan M; Yadav VS; Bhatia AS
    Acta Leprol; 1995; 9(3):133-7. PubMed ID: 7631584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological changes in tuberculoid leprosy after fixed duration multidrug therapy for six months.
    Lavania RK; Girdhar A; Girdhar BK; Desikan KV
    Acta Leprol; 1990; 7(2):169-74. PubMed ID: 2220301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of multidrug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):436-44. PubMed ID: 1474282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of multidrug therapy in paucibacillary leprosy.
    Kar PK; Sohi AS
    J Indian Med Assoc; 1989 Feb; 87(2):34-6. PubMed ID: 2674283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and histopathological activity in paucibacillary leprosy patients after fixed-duration multidrug therapy.
    Ebenezer GJ; Suneetha S; Arunthathi S
    Lepr Rev; 1997 Sep; 68(3):218-24. PubMed ID: 9364822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapses in paucibacillary leprosy after MDT--a clinical study.
    Grugni A; Nadkarni NJ; Kini MS; Mehta VR
    Int J Lepr Other Mycobact Dis; 1990 Mar; 58(1):19-24. PubMed ID: 2319185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence and management of leprosy reaction in China in 2005.
    Shen J; Liu M; Zhou M; Wengzhong L
    Lepr Rev; 2009 Jun; 80(2):164-9. PubMed ID: 19743620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug therapy for treatment of paucibacillary leprosy in western Kenya--preliminary communications.
    Orege PA; Obura M; Okelo C; Okuku P; Makokha S; Nyawalo J
    East Afr Med J; 1990 Sep; 67(9):632-9. PubMed ID: 2253572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed duration MDT in paucibacillary leprosy (classical and modified).
    Nadkarni NJ; Grugni A; Kini MS
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):25-8. PubMed ID: 8326177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse of paucibacillary leprosy after short course multidrug therapy.
    Pavithran K
    Indian J Lepr; 1988 Apr; 60(2):225-9. PubMed ID: 3192971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.